RxDoctor Payments DataLook up a doctor →

James Tilley, MD

General Practice · Conway, ARNPI 1932178332

Payments from drug & device makers

$7,668in general payments, 2019–2025

Across 512 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$902
  • Novo Nordisk$721
  • AstraZeneca$666
  • GSK$637
  • Lilly USA, LLC$427
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,668 in reported general payments places this provider in the 95th percentile of 720 general practice providers in Arkansas.

See all general practice providers in Arkansas

Medicare billing

Part B allowed, 2024
$483,299
Medicare patients
663
Services billed
10,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin240$132,665
OzempicSemaglutide119$118,962
MounjaroTirzepatide97$99,368
EliquisApixaban162$85,827
XareltoRivaroxaban69$71,171
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$63,896
TrulicityDulaglutide44$43,257
JanuviaSitagliptin Phosphate66$40,169
RexultiBrexpiprazole42$31,972
Tresiba Flextouch U-200Insulin Degludec25$28,446
Breo ElliptaFluticasone/Vilanterol55$26,008
FarxigaDapagliflozin Propanediol33$19,393
LinzessLinaclotide23$16,675
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$14,286
TresibaInsulin Degludec24$11,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$427$142,625141 claims
Boehringer IngelheimJardiance$56$132,665240 claims
Novo NordiskOzempic, Tresiba$721$130,835143 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$637$101,469154 claims
PfizerEliquis$902$85,827162 claims
Johnson & JohnsonXarelto, Invokana$254$77,83184 claims
MerckJanuvia$23$40,16966 claims
Otsuka America Pharmaceutical, Inc.Rexulti$225$31,97242 claims
AstraZenecaFarxiga, Symbicort$666$23,53450 claims
AbbVieLinzess, Synthroid$1,173$19,91284 claims
Sanofi-aventis U.S. LLCMultaq$39$9,80612 claims
NovartisEntresto$77$9,28211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 720 general practice providers in Arkansas.

Other general practice in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →